Vaccination for adult patients with functional or anatomic asplenia

Vaccines needed: (1) Haemophilus influenzae type B vaccine, (2) Meningococcus serogroups A, C, Y, W vaccine, (3) Meningococcus serogroup B vaccine, and (4) Pneumococcus vaccine. It is safe to give all four vaccines at the same time, in different injection sites.

1. Haemophilus influenzae type B vaccine
   a. One dose (0.5 mL IM) once

2. Meningococcus Serogroups A, C, Y, W vaccines
   a. Two commercially available vaccines (Menveo is preferred):
      i. Menveo®
         1. Administer 2 doses (each dose 0.5 mL IM) at least 2 months apart and revaccinate every 5 years
      ii. Menactra®
         1. Administer 2 doses (each dose 0.5 mL IM) at least 2 months apart and revaccinate every 5 years
            a. Menactra® interferes with antibody response of Prevnar® in pediatric studies. Therefore, it is not recommended to administer Menactra® and Prevnar® concomitantly.
            b. If only Menactra® is available for administration, it is recommended to administer Prevnar® first and administer Menactra® 4 weeks after Prevnar®
      iii. Menveo® and Menactra® are otherwise interchangeable for persons age 9 months and older

3. Meningococcus Serogroup B vaccine
   a. Two commercially available vaccines (either vaccines can be used)
      i. Trumenba®
         1. 3-dose series (each dose 0.5 mL IM) administered at 0, 2, 6 months
      ii. Bexsero®
         1. 2-dose series (each dose 0.5 mL IM) administered at 0 and 1 month
   b. Trumenba® and Bexsero® vaccines are not interchangeable – patients must complete the series with the same vaccine.
   c. Trumenba® or Bexsero® can be administered with Menveo® (Meningococcus Serogroup A,C,Y,W) at the same time but should be administered at different anatomic sites.

4. Pneumococcal vaccines - 2 types of pneumococcal vaccines needed
   a. Pneumococcal vaccine-naïve patients aged 19 years to 64 years should receive a dose of Prevnar® (PCV13) first, followed by a dose of Pneumovax® (PPSV23) at least 8 weeks later and a second dose of Pneumovax® at least 5 years after the first Pneumovax
   b. Pneumococcal vaccine-naïve patients aged ≥ 65 years should receive a dose of Prevnar® (PCV13) first, followed by a dose of Pneumovax® (PPSV23) at least 8 weeks later. No second dose of Pneumovax® is recommended by ACIP at this time.
   c. Patients with history of prior receipt of pneumococcal vaccines – See Algorithm below
Patients (age 19 to < 65 years) with functional or anatomic asplenia - Pneumococcal Vaccine Schedule

Elective splenectomy - patients should be vaccinated at least 2 weeks before an elective splenectomy
Non-elective splenectomy – patients should be vaccinated as soon as patient is stable

**Adult Asplenic Patient**

**Age 19 to < 65 years**

- No history of any Pneumococcal vaccine or Unknown history
  - **PCV13**
    - After at least 8 weeks
  - **PPSV23**
    - After at least 5 years

- History of 1 dose of PPSV23
  - **PCV13**
    - At least 1 year after PPSV23
  - **PPSV23**
    - At least 8 weeks after PCV13

- History of 2 doses of PPSV23
  - **PCV13**
    - At least 1 year after the most recent dose of PPSV23
  - **PPSV23**
    - At least 8 weeks after PCV13

- History of 1 dose of PCV13
  - **PPSV23**
    - At least 5 years after 1st dose of PPSV23
  - **PPSV23**
    - At least 5 years after the first dose of PPSV23

- History of 1 dose of PCV13 and 1 dose of PPSV23
  - **PPSV23**
    - At least 8 weeks after PCV13 and at least 5 years after PPSV23

**PCV13**: 13-valent Pneumococcal Conjugate Vaccine
**PPSV23**: 23-valent Pneumococcal Polysaccharide Vaccine
Patients (age ≥ 65 years) with functional or anatomic asplenia - Pneumococcal Vaccine Schedule

Elective splenectomy - patients should be vaccinated at least 2 weeks before an elective splenectomy
Non-elective splenectomy – patients should be vaccinated as soon as patient is stable

**Adult Asplenic Patient**
**Age ≥ 65 years**

- **No history of any Pneumococcal vaccine or Unknown history**
  - **PCV13**
  - After at least 8 weeks
  - **PPSV23**

- **Have NOT received PCV13 and received 1 dose of PPSV23 at age ≥ 65 years**
  - **PCV13**
  - At least 1 year after PPSV23
  - **PCV13**
  - At least 8 weeks after PCV13 and at least 5 years after PPSV23
  - **PPSV23**

- **Have NOT received PCV13 and received 1 or more doses of PPSV23 at age < 65 years**
  - **PCV13**
  - At least 1 year after the most recent dose of PPSV23
  - **PCV13**
  - At least 8 weeks after PCV13 and at least 5 years after PPSV23
  - **PPSV23**

- **Received PCV13 and Not PPSV23 at age < 65 years**
  - **PCV13**
  - At least 1 year after PPSV23
  - **PPSV23**

- **Received PCV13 and 1 or more doses PPSV23 at age < 65 years**
  - **PCV13**
  - At least 8 weeks after PCV13 and at least 5 years after PPSV23
  - **PPSV23**

- **History of received PCV13 and PPSV23 after age ≥ 65 years**
  - **No pneumococcal vaccination needed**

**PCV13**: 13-valent Pneumococcal Conjugate Vaccine

**PPSV23**: 23-valent Pneumococcal Polysaccharide Vaccine